FIGURE 4. Major cytogenetic response rates relative to daily dose of dasatinib.

FIGURE 4Major cytogenetic response rates relative to daily dose of dasatinib

Dose categories include totals of once-daily and twice-daily administrations; the area of the bubbles is inversely proportional to the variance of each estimate.

From: 2, Assessment of clinical effectiveness

Cover of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.22.
Rogers G, Hoyle M, Thompson Coon J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.